Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

Cancer Immunology, Immunotherapy : CII
Lotte Engell-NoerregaardInge Marie Svane

Abstract

During the past years numerous clinical trials have been carried out to assess the ability of dendritic cell (DC) based immunotherapy to induce clinically relevant immune responses in patients with malignant diseases. A broad range of cancer types have been targeted including malignant melanoma which in the disseminated stage have a very poor prognosis and only limited treatment options with moderate effectiveness. Herein we describe the results of a focused search of recently published clinical studies on dendritic cell vaccination in melanoma and review different vaccine parameters which are frequently claimed to have a possible influence on clinical response. These parameters include performance status, type of antigen, DC maturation status, route of vaccine administration, use of adjuvant, and vaccine induced immune response. In total, 38 articles found through Medline search, have been included for analysis covering a total of 626 patients with malignant melanoma treated with DC based therapy. Clinical response (CR, PR and SD) were found to be significantly correlated with the use of peptide antigens (p = 0.03), the use of any helper antigen/adjuvant (p = 0.002), and induction of antigen specific T cells (p = 0.0004). No s...Continue Reading

References

Apr 1, 1998·Nature·J Banchereau, R M Steinman
Dec 10, 1998·International Immunology·A SnijdersM L Kapsenberg
Apr 13, 2000·International Journal of Cancer. Journal International Du Cancer·A MackensenA Lindemann
Jun 3, 2000·Annual Review of Immunology·J BanchereauK Palucka
Mar 10, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·B LudewigR M Zinkernagel
Mar 10, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·L FongE G Engleman
May 24, 2001·Immunity·C Reis e Sousa
Mar 5, 2003·Trends in Immunology·Adrian E Morelli, Angus W Thomson
Apr 12, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Marc DauerAndreas Eigler
Apr 19, 2003·Cancer Immunology, Immunotherapy : CII·Michael G E O'RourkeChristopher W Schmidt
Oct 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Isabelle BedrosianBrian J Czerniecki
Nov 6, 2003·Cancer Immunology, Immunotherapy : CII·Peter HerseyMargaret Lett
Jan 29, 2005·Journal of Translational Medicine·Yasuto AkiyamaKen Yamaguchi
Mar 8, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Zhen SuJohannes Vieweg
Mar 8, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yukai HeLouis D Falo
Sep 28, 2005·Cancer Immunology, Immunotherapy : CII·Margarita SalcedoThierry Velu
Oct 27, 2005·Current Pharmaceutical Design·Farid SalehAbdullah Behbehani
Nov 10, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gerald P LinetteFrank G Haluska
Jan 19, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D SchadendorfUNKNOWN DC study group of the DeCOG
Apr 14, 2006·Cancer Immunology, Immunotherapy : CII·Jon A Kyte, Gustav Gaudernack

❮ Previous
Next ❯

Citations

Jan 25, 2011·Cancer Immunology, Immunotherapy : CII·Luciano CastielloDavid F Stroncek
Jun 17, 2010·Journal of Immunotherapy·Doru T AlexandrescuConstantin A Dasanu
Jun 29, 2010·Pigment Cell & Melanoma Research·Noriaki NakaiNorito Katoh
Oct 5, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard J BarthMarc S Ernstoff
Jul 23, 2013·The Journal of Clinical Investigation·Beatriz M CarrenoGerald P Linette
Jan 14, 2011·Journal of Immune Based Therapies and Vaccines·Sandra Tuyaerts
Jun 14, 2013·PloS One·Stephanie WallnerDominik Wolf
Jul 20, 2010·Immunotherapy·Elzbieta Pajtasz-Piasecka, Marie Indrová
Dec 23, 2010·Immunotherapy·Yasuhiko NishiokaSaburo Sone
Oct 15, 2011·Immunotherapy·Beatrix KotlanMichael R Shurin
Apr 6, 2011·Immunotherapy·John CopierAngus Dalgleish
May 24, 2011·World Journal of Clinical Oncology·Ali Syed Arbab
Sep 17, 2014·Expert Review of Clinical Immunology·Marco TucciFranco Silvestris
Apr 25, 2014·Expert Review of Vaccines·Laetitia CiccheleroNiek N Sanders
Apr 27, 2010·Expert Opinion on Biological Therapy·Theresa L Whiteside
Feb 12, 2014·Current Opinion in Immunology·Kristen J RadfordMireille H Lahoud
Jan 23, 2016·Journal of Surgical Oncology·Kerri A SimoJohn B Martinie
Feb 24, 2010·Molecular Aspects of Medicine·Zhenyu JiHensin Tsao
Feb 2, 2010·Current Opinion in Immunology·Neil C RobsonMax Schnurr
Dec 1, 2009·Neurosurgery Clinics of North America·Won Kim, Linda M Liau
Nov 17, 2009·Clinics in Plastic Surgery·Jonathan Treisman, Nina Garlie
Oct 13, 2009·Human Immunology·Kim HolmstrømSimon Skjøde Jensen
Jun 15, 2012·The Journal of Investigative Dermatology·Caroline AspordJoel Plumas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.